Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective
Heithem Soliman(Hôpital Louis-Mourier), Vinciane Rebours(Hôpital Beaujon), Marie‐Pierre Vullierme, Philippe Lévy(Hôpital Beaujon), Philippe Ruszniewski(Inserm), Frédérique Maire(Université Paris Cité), Olivia Hentic(Université Paris Cité)
Cited by 54
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
|Annals of Oncology|2015|698
Determinant-Based Classification of Acute Pancreatitis Severity
|Annals of Surgery|2012|516